logo-loader
viewHelix BioPharma Corp.

Helix BioPharma Corp seeing good progress in clinical trials of cancer-fighting drug

Patient enrollment and screening commenced on the LDOS006 Phase Ib/II clinical study in the US for the treatment of patients with previously treated advanced pancreatic cancer

doctors looking at xray
L-DOS47 is currently in clinical trials for the treatment of non-squamous small cell lung cancer and pancreatic cancer

Helix BioPharma Corp (TSE:HBP) (OTCMKTS:HBPCF) is advancing its research into its patented cancer-fighting technology platform, with studies currently ongoing in the US.

L-DOS47 is currently in clinical trials for the treatment of non-squamous small cell lung cancer and pancreatic cancer. The Toronto-based company has launched a Phase I clinical study in the US, with a Phase Ib/II trial recently approved to go ahead.

READ: Helix BioPharma closes C$6 million private placement

Meanwhile, patient enrollment and screening commenced on the LDOS006 Phase Ib/II clinical study in the US for the treatment of patients with previously treated advanced pancreatic cancer, Helix revealed on Tuesday. Two patients have been enrolled to date, according to the company.

The Phase Ib portion of the study will test nine patients on three dose-escalating cohorts, while the Phase II portion will enroll an additional 11 patients depending on meeting safety and efficacy criteria, Helix told investors.

Helix spent around C$1.6 million in research and development costs during its fiscal second quarter ended January 31, 2020.

The company is also in the process of divesting its stake in a Polish subsidiary, which it hopes to complete before the end of fiscal 2020. Proceeds from the remaining 51% stake will fund clinical development programs. Helix will retain licensing agreements for future royalties and milestone payments.

The firm reported a net loss of C$2,255,000 during the three-month period ended January 31 or C$0.02 per share compared to a loss of C$1.9 million or C$0.02 per share a year prior.

Helix said it is currently looking to raise additional capital to advance its clinical development program and qualify for a NASDAQ listing.

On Monday, the company closed a C$6 million financing to support research and development.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Helix BioPharma Corp.

Price: 0.88 CAD

TSX:HBP
Market: TSX
Market Cap: $116.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Helix BioPharma Corp. named herein, including the promotion by the Company of Helix BioPharma Corp. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Helix BioPharma closes financing as they look to uplist to...

Helix BioPharma (TSE: HBP) CEO Dr Heman Chao sat down with Steve Darling from Proactive in New York to share details they have just completed a fundraise. Chao also talked about his desire to uplist the company to the Nasdaq.  Dr Chao also told Proactive what is planned this year in the...

on 6/2/20

2 min read